Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services Administration (HRSA) website.
The products include four NDCs for Merck’s antiviral Intron A and one NDC for its antiviral Sylatron. TICE BCG, a treatment for non-metastatic bladder cancer, also is covered. Merck has been allocating its supplies of TICE BCG due to supply constraints since January 2019.
Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new
public notice on the U.S. Health Resources and Services Administration (HRSA) website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
